Sam J. Lubner, MD close
Sam J. Lubner, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Sam J. Lubner, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Lubner graduated from Princeton University, Princeton, NJ, with a BA in History in 1999, and the University of Wisconsin School of Medicine and Public Health (formerly UW Medical School), Madison, WI with a MD, in 2003. His postgraduate internship and residency training in Internal Medicine was performed at Washington University School of Medicine, Barnes-Jewish Hospital, Saint Louis, MO from 2003 to 2006, and a fellowship in Hematology/Oncology at University of Wisconsin Hospital and Clinics, Madison, WI.



UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
University Hospital
(608) 263-7502 | (800) 323-8942 | Map
Beaver Dam Community Hospital
(920) 887-4105 | (888) 703-2778 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency Barnes-Jewish Hospital, St. Louis, MO
Internship Barnes-Jewish Hospital, St. Louis, MO
Medical School University of Wisconsin School of Medicine and Public Health (formerly UW Medical School), Madison, WI

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
PubMed Articles
Cherukuri AR Lubner MG Zea R Hinshaw JL Lubner SJ Matkowskyj KA Foltz ML Pickhardt PJ Tissue sampling in the era of precision medicine: comparison of percutaneous biopsies performed for clinical trials or tumor genomics versus routine clinical care. Abdom Radiol (NY) . 2019 Jun;44(6):2074-2080
[PubMed ID: 30032384]
Sahai V Catalano PJ Zalupski MM Lubner SJ Menge MR Nimeiri HS Munshi HG Benson AB 3rd O'Dwyer PJ Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol . 2018 Dec 1;4(12):1707-1712
[PubMed ID: 30178032]
Kupfer SS Lubner S Coronel E Pickhardt PJ Tipping M Graffy P Keenan E Ross E Li T Weinberg DS Adherence to postresection colorectal cancer surveillance at National Cancer Institute-designated Comprehensive Cancer Centers. Cancer Med . 2018 Nov;7(11):5351-5358
[PubMed ID: 30338661]
Lubner S Feng Y Mulcahy M O'Dwyer P Giang GY Hinshaw JL Deming D Klein L Teitelbaum U Payne J Engstrom P Stella P Meropol N Benson A E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist . 2018 Sep;23(9):1006-e104
[PubMed ID: 29853660]
Weinberg DS Pickhardt PJ Bruining DH Edwards K Fletcher JG Gollub MJ Keenan EM Kupfer SS Li T Lubner SJ Markowitz AJ Ross EA Computed Tomography Colonography vs Colonoscopy for Colorectal Cancer Surveillance After Surgery. Gastroenterology . 2018 Mar;154(4):927-934.e4
[PubMed ID: 29174927]
Lubner MG Stabo N Lubner SJ Del Rio AM Song C Pickhardt PJ Volumetric Versus Unidimensional Measures of Metastatic Colorectal Cancer in Assessing Disease Response. Clin Colorectal Cancer . 2017 Dec;16(4):324-333.e1
[PubMed ID: 28433601]
Pickhardt PJ Edwards K Bruining DH Gollub M Kupfer S Lubner SJ Kim DH Ross E Keenan E Weinberg DS Prospective Trial Evaluating the Surgical Anastomosis at One-Year Colorectal Cancer Surveillance: CT Colonography Versus Optical Colonoscopy and Implications for Patient Care. Dis Colon Rectum . 2017 Nov;60(11):1162-1167
[PubMed ID: 28991080]
Lubner SJ Uboha NV Deming DA Primary and acquired resistance to biologic therapies in gastrointestinal cancers. J Gastrointest Oncol . 2017 Jun;8(3):499-512
[PubMed ID: 28736637]
Thomas MJ Bartlett HL Bassetti MF Lubner SJ Kirvassilis G Anagnostopoulos PV Maloney JD Macke RA Minimally Invasive Esophagectomy in a Patient With Tetralogy of Fallot and Right-Sided Aortic Arch. Ann Thorac Surg . 2017 Jan;103(1):e77-e79
[PubMed ID: 28007281]
Sievers CK Kratz JD Zurbriggen LD LoConte NK Lubner SJ Uboha N Mulkerin D Matkowskyj KA Deming DA The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms. Clin Colon Rectal Surg . 2016 Sep;29(3):232-8
[PubMed ID: 27582648]
Jin N Lubner SJ Mulkerin DL Rajguru S Carmichael L Chen H Holen KD LoConte NK A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors. Oncologist . 2016 Jul;21(7):785-6
[PubMed ID: 27261467]
Deming DA Cavalcante LL Lubner SJ Mulkerin DL LoConte NK Eickhoff JC Kolesar JM Fioravanti S Greten TF Compton K Doyle AG Wilding G Duffy A Liu G A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest New Drugs . 2016 Apr;34(2):168-75
[PubMed ID: 26666244]
Deming D Uboha N Zafar SY Rosenberg S Bassetti M Glasgow S Borden EC Lubner S Adjuvant Chemotherapy for Stage II Rectal Cancer. Semin Oncol . 2015 Dec;42(6):e99-107
[PubMed ID: 26615141]
Lubner MG Stabo N Lubner SJ del Rio AM Song C Halberg RB Pickhardt PJ CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes. Abdom Imaging . 2015 Oct;40(7):2331-7
[PubMed ID: 25968046]
Tran NH Cavalcante LL Lubner SJ Mulkerin DL LoConte NK Clipson L Matkowskyj KA Deming DA Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol . 2015 Sep;7(5):252-62
[PubMed ID: 26327923]
Makielski RJ Lubner SJ Mulkerin DL Traynor AM Groteluschen D Eickhoff J LoConte NK A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer. Cancer Chemother Pharmacol . 2015 Aug;76(2):317-23
[PubMed ID: 26068189]
LoConte NK Razak AR Ivy P Tevaarwerk A Leverence R Kolesar J Siu L Lubner SJ Mulkerin DL Schelman WR Deming DA Holen KD Carmichael L Eickhoff J Liu G A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs . 2015 Feb;33(1):169-76
[PubMed ID: 25318436]
Lubner SJ Mullvain J Perlman S Pishvaian M Mortimer J Oliver K Heideman J Hall L Weichert J Liu G A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies. Cancer Invest . 2015;33(10):483-9
[PubMed ID: 26536061]
Halverson JL Martinez-Donate AP Palta M Leal T Lubner S Walsh MC Schaaf Strickland J Smith PD Trentham-Dietz A Health Literacy and Health-Related Quality of Life Among a Population-Based Sample of Cancer Patients. J Health Commun . 2015;20(11):1320-9
[PubMed ID: 26161549]
Deming DA Maher ME Leystra AA Grudzinski JP Clipson L Albrecht DM Washington MK Matkowskyj KA Hall LT Lubner SJ Weichert JP Halberg RB Phospholipid ether analogs for the detection of colorectal tumors. PLoS One . 2014;9(10):e109668
[PubMed ID: 25286226]